Evergreen Wealth Management LLC Purchases Shares of 5,653 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Evergreen Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 5,653 shares of the biopharmaceutical company's stock, valued at approximately $3,585,000. Regeneron Pharmaceuticals makes up about 2.1% of Evergreen Wealth Management LLC's portfolio, making the stock its 18th largest holding.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Pinney & Scofield Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at about $25,000. E Fund Management Hong Kong Co. Ltd. lifted its stake in shares of Regeneron Pharmaceuticals by 344.4% in the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 31 shares during the period. Tompkins Financial Corp acquired a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at about $32,000. Curat Global LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at about $32,000. Finally, Crowley Wealth Management Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at about $36,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Trading Down 1.4%

REGN stock traded down $7.48 during mid-day trading on Friday, reaching $542.52. 1,307,803 shares of the stock traded hands, compared to its average volume of 929,805. The stock's fifty day moving average is $544.44 and its 200-day moving average is $614.31. The company has a current ratio of 4.93, a quick ratio of 4.03 and a debt-to-equity ratio of 0.09. The company has a market cap of $58.57 billion, a P/E ratio of 13.81, a P/E/G ratio of 2.01 and a beta of 0.33. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). The company had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The company's revenue for the quarter was down 3.7% on a year-over-year basis. During the same quarter last year, the business earned $9.55 EPS. As a group, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were issued a dividend of $0.88 per share. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.65%. Regeneron Pharmaceuticals's payout ratio is presently 8.96%.

Analysts Set New Price Targets

REGN has been the subject of several recent analyst reports. Argus cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Monday, June 30th. Wells Fargo & Company cut shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and cut their target price for the stock from $700.00 to $580.00 in a research report on Friday, May 30th. Wall Street Zen cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 1st. BMO Capital Markets cut their target price on shares of Regeneron Pharmaceuticals from $800.00 to $600.00 and set an "outperform" rating for the company in a research report on Monday, June 2nd. Finally, Truist Financial cut their target price on shares of Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have issued a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $823.54.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.